Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depemokimab for adults with uncontrolled COPD with type 2 inflammation (ENDURA-2)
MOH_2025-09-29_014365Phase 3Not yet recruiting
- Sponsor
- GSK
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Depemokimab with Placebo (2 arms). Primary endpoint: Annualized rate of moderate/severe COPD exacerbations. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
depemokimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on MOH_2025-09-29_014365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-09-29_014365.